Oxford Instruments: Berenberg upgrades to buy with a target price of 1,180p.
AIM-listed life sciences group Abzena said on Monday that its collaboration and licence agreement with Halozyme Therapeutics relating to the use of its ThioBridge linker technology for the development of antibody drug conjugate products has been terminated.
AIM-listed life sciences group Abzena said on Friday that it had moved into new headquarters on the Babraham Research Campus in Cambridge.
Melbourne, Australia based biopharmaceutical company Telix have signed a proprietary licencing agreement with Abzena out of Cambridge for their prostate-specific membrane antigen (PSMA).
Life sciences group Abzena signed a licensing agreement and a master services and clinical supply agreement with OBI Pharma, a Taiwanese biopharmaceutical company, it announced on Tuesday.
Shares in Abzena zipped up almost 12% after the life sciences group said development partner True North Therapeutics Inc has been acquired by Bioverativ Inc for $400m.
Life science firm Abzena, which provides services and technologies for the manufacture of biopharmaceutical products, is planning to raise about £25m in order to expand its service offering to customers.
One of life-science company Abzena's composite human antibody is to move to a phase two clinical trial.
Abzena sees full-year group revenues in line with its expectations, saying first-half momentum and strong demand for services has continued.
Life sciences group Abzena announced on Friday that it has signed a licensing agreement with an unnamed San Diego-based biopharmaceutical company for its site-specific 'ThioBridge' antibody drug conjugate linker technology.
Life-sciences group Abzena has inked a licence agreement with start-up biotechnology company Trieza Therapeutics.
Life sciences group Abzena noted on Wednesday that during Gilead Sciences' announcement of third quarter earnings on 1 November, it stated that no further development of simtuzumab will be pursued.
Life sciences group Abzena noted on Friday that Gilead Sciences has announced top line Phase II clinical study results of its product, GS-4997 (selonsertib) in combination with the investigational monoclonal antibody, simtuzumab (SIM) or SIM alone, in patients with non-alcoholic steatohepatitis (NASH).
Life sciences company Abzena announced that Roche has acquired Adheron Therapeutics, which is a privately-held biotechnology company developing the SPD051 product that disrupts cell adhesion using Abzena's Composite Human Antibody technology.
Life sciences group Abzena has completed the acquisition of biopharmaceutical development and manufacturing company PacificGMP for $7.7m in cash and stock.